Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:GLMD News 17 November 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. announced fresh results from its ongoing collaboration with Virginia Commonwealth University (VCU) on overcoming drug resistance in GI cancers. Galmed Pharmaceuticals+1 The headline: A three‑drug combination of Aramchol + Stivarga + metformin produced a synergistic anti‑tumor effect, significantly enhancing GI tumor cell killing both in vitro and in vivo. According to today’s press release
17 November 2025
···

Stock Market Today

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Shanghai, Feb 8, 2026, 10:25 CST — Market closed Shenzhen Longsys Electronics Co., Ltd.’s Class A shares head into Monday’s reopen after the memory products maker flagged new guarantees for overseas units in a late-Friday filing. It is not an earnings update. But it lands on a market that has started to look harder at cash needs, debt and offshore exposure across China’s fast-rerating chip names. For Longsys, the timing matters because the filing highlights how much of the group’s funding is still supported by parent-company guarantees, even as it runs procurement and manufacturing footprints outside mainland China. In the
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop